147 research outputs found
Mobility of thorium ions in liquid xenon
We present a measurement of the Th ion mobility in LXe at 163.0 K and
0.9 bar. The result obtained, 0.2400.011 (stat) 0.011 (syst)
cm/(kV-s), is compared with a popular model of ion transport.Comment: 6.5 pages,
A simple radionuclide-driven single-ion source
We describe a source capable of producing single barium ions through nuclear
recoils in radioactive decay. The source is fabricated by electroplating 148Gd
onto a silicon {\alpha}-particle detector and vapor depositing a layer of BaF2
over it. 144Sm recoils from the alpha decay of 148Gd are used to dislodge Ba+
ions from the BaF2 layer and emit them in the surrounding environment. The
simultaneous detection of an {\alpha} particle in the substrate detector allows
for tagging of the nuclear decay and of the Ba+ emission. The source is simple,
durable, and can be manipulated and used in different environments. We discuss
the fabrication process, which can be easily adapted to emit most other
chemical species, and the performance of the source
A liquid xenon ionization chamber in an all-fluoropolymer vessel
A novel technique has been developed to build vessels for liquid xenon
ionization detectors entirely out of ultra-clean fluoropolymer. We describe the
advantages in terms of low radioactivity contamination, provide some details of
the construction techniques, and show the energy resolution achieved with a
prototype all-fluoropolymer ionization detector.Comment: 12 pages, 9 figure
A magnetically-driven piston pump for ultra-clean applications
A magnetically driven piston pump for xenon gas recirculation is presented.
The pump is designed to satisfy extreme purity and containment requirements, as
is appropriate for the recirculation of isotopically enriched xenon through the
purification system and large liquid xenon TPC of EXO-200. The pump, using
sprung polymer gaskets, is capable of pumping more than 16 standard liters per
minute (SLPM) of xenon gas with 750 torr differential pressure.Comment: 6 pages, 5 figure
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
BACKGROUND: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.
METHODS AND FINDINGS: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements 500 copies/µl, the first of two consecutive measurements between 50-500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30-0.40) for counts <200 cells/µl, 0.81 (0.71-0.92) for counts 200 to <350 cells/µl, 0.74 (0.66-0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92-0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl.
CONCLUSIONS: Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl
A xenon gas purity monitor for EXO
We discuss the design, operation, and calibration of two versions of a xenon
gas purity monitor (GPM) developed for the EXO double beta decay program. The
devices are sensitive to concentrations of oxygen well below 1 ppb at an
ambient gas pressure of one atmosphere or more. The theory of operation of the
GPM is discussed along with the interactions of oxygen and other impurities
with the GPM's tungsten filament. Lab tests and experiences in commissioning
the EXO-200 double beta decay experiment are described. These devices can also
be used on other noble gases.Comment: 41 pages, 26 figure
Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis
BACKGROUND:
Aspecific scoring systems are used to predict the risk of death postsurgery in patients with infective endocarditis (IE). The purpose of the present study was both to analyze the risk factors for in-hospital death, which complicates surgery for IE, and to create a mortality risk score based on the results of this analysis.
METHODS AND RESULTS:
Outcomes of 361 consecutive patients (mean age, 59.1\ub115.4 years) who had undergone surgery for IE in 8 European centers of cardiac surgery were recorded prospectively, and a risk factor analysis (multivariable logistic regression) for in-hospital death was performed. The discriminatory power of a new predictive scoring system was assessed with the receiver operating characteristic curve analysis. Score validation procedures were carried out. Fifty-six (15.5%) patients died postsurgery. BMI >27 kg/m2 (odds ratio [OR], 1.79; P=0.049), estimated glomerular filtration rate 55 mm Hg (OR, 1.78; P=0.032), and critical state (OR, 2.37; P=0.017) were independent predictors of in-hospital death. A scoring system was devised to predict in-hospital death postsurgery for IE (area under the receiver operating characteristic curve, 0.780; 95% CI, 0.734-0.822). The score performed better than 5 of 6 scoring systems for in-hospital death after cardiac surgery that were considered.
CONCLUSIONS:
A simple scoring system based on risk factors for in-hospital death was specifically created to predict mortality risk postsurgery in patients with IE
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
INTRODUCTION: Since the beginning of the HIV epidemic in resource-rich countries, Pneumocystis jirovecii pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy. Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much lower population at risk. METHODS: We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons >16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a restricted cubic spline, and HIV-RNA was stratified as low (10,000copies/mL). RESULTS: There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the different plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4 counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI: 2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7). CONCLUSIONS: HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4 counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts rise above 200 cells/mL, the latest US Guidelines consider secondary prophylaxis discontinuation even in patients with a CD4 count above 100 cells/µL and suppressed viral load. Our results strengthen and support this US recommendation
- …